logo
CreditAccess Grameen surges 9%, stock nears 52-week high; here's why

CreditAccess Grameen surges 9%, stock nears 52-week high; here's why

CreditAccess Grameen share price
Shares of CreditAccess Grameen surged 9 per cent to ₹1,355 on the BSE in Friday's intra-day trade amid heavy volumes after the company's business momentum improved, coupled with stabilizing asset quality in the June 2025 quarter (Q1FY26).
With today's rally, the stock price of CreditAccess Grameen has recovered 81 per cent from its 52-week low of ₹750.05 touched on January 27, 2025. It had hit a 52-week high of ₹1,369.25 on July 4, 2024.
At 10:14 AM; the stock was trading 7 per cent higher at ₹1,329.60, as compared to 0.01 per cent rise in the BSE Sensex. The average trading volumes at the counter jumped nearly 10-fold, with a combined 3.82 million shares changing hands on the NSE and BSE.
CreditAccess Grameen Q1FY26 update
CreditAccess Grameen has reported a marginal 0.4 per cent quarter-on-quarter (QoQ) rise in gross loan portfolio (GLP) to ₹26,055 crore in the June 2025 quarter (Q1FY26), reflecting modest growth post write-offs of ₹693 crore. The microfinance institutions (MFI) had posted GLP of ₹25,948 crore in Q4FY25.
Karnataka GLP increased slightly to ₹8,104 crore (vs. ₹8,068 crore in Q4), while other states' GLP rose to ₹17,951 crore (vs. ₹17,879 crore). Portfolio at Risk metrics showed improvement: overall PAR 0+ declined to 5.9 per cent (vs. 6.9 per cent in Q4), with PAR 0+ excluding Karnataka dropping to 4.4 per cent (vs. 6.1 per cent). The company added ~2 lakh new borrowers during the quarter supporting continued business momentum.
CreditAccess Grameen said the Q1FY26 sets a new benchmark, driven by highest first quarter disbursement and strong business momentum. The company delivered a healthy QoQ growth of 3.1 per cent (pre write-off basis) while fully adhering with MFIN Guardrails.
Considering the evolving business environment, the management in May month said that they are aiming for asset under management (AUM) growth of 14-18 per cent of which MFI growth will be 8-12 per cent and the balance from retail finance, NIM of 12.6-12.8 per cent, credit cost of 5.5-6.0 per cent, ROA of 2.9-3.4 per cent and ROE of 11.8-13.3 per cent in FY26.
Brokerages view on CreditAccess Grameen
Improving asset quality and gradual stabilization in performance post accelerated write-offs; sustained improvement in collection efficiency indicates gradual recovery. However, higher exposure in Karnataka amid concerns on collections remains watchful, ICICI Securities said in a note.
A trend reversal is on the horizon in the MFI sector and is expected to play out over the next couple of quarters, with the sector likely nearing normalization by H2FY26. That said, Motilal Oswal Financial Services strongly believes that the upcoming three months present an opportunity to separate high-quality franchises from weaker ones, with performance divergence across the MFI sector expected to be increasingly evident.
Backed by a strong capital position (Tier-1 of ~24 per cent), CreditAccess Grameen is well-placed to embark on a healthy loan growth trajectory as delinquency trends show further signs of normalization. CreditAccess Grameen trades at 2.0x FY27E P/BV, and its premium valuation over MFI peers is likely to sustain, driven by stronger confidence in its ability to return to normalcy ahead of its peers, the brokerage firm said.
About CreditAccess Grameen
CreditAccess Grameen is a leading Indian microfinance institution headquartered in Bengaluru, focused on providing micro-loans to women customers predominantly in rural areas across India. The company is now operating across 423 districts in 16 states and one union territory (Puducherry) through 2,063 branches. The company's promoter is CreditAccess India B.V., a multinational company specializing in micro and small enterprise financing. It is backed by institutional investors and has a micro-lending experience in India of more than a decade.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nuvama Wealth Management Ltd leads losers in 'A' group
Nuvama Wealth Management Ltd leads losers in 'A' group

Business Standard

time30 minutes ago

  • Business Standard

Nuvama Wealth Management Ltd leads losers in 'A' group

Trent Ltd, Sammaan Capital Ltd, Angel One Ltd and Authum Investment & Infrastructure Ltd are among the other losers in the BSE's 'A' group today, 04 July 2025. Trent Ltd, Sammaan Capital Ltd, Angel One Ltd and Authum Investment & Infrastructure Ltd are among the other losers in the BSE's 'A' group today, 04 July 2025. Nuvama Wealth Management Ltd crashed 11.12% to Rs 7274.75 at 14:46 stock was the biggest loser in the BSE's 'A' the BSE, 57192 shares were traded on the counter so far as against the average daily volumes of 7896 shares in the past one month. Trent Ltd lost 11.07% to Rs 5501.6. The stock was the second biggest loser in 'A' the BSE, 3.32 lakh shares were traded on the counter so far as against the average daily volumes of 41994 shares in the past one month. Sammaan Capital Ltd tumbled 8.86% to Rs 123.5. The stock was the third biggest loser in 'A' the BSE, 23.26 lakh shares were traded on the counter so far as against the average daily volumes of 5.76 lakh shares in the past one month. Angel One Ltd slipped 6.40% to Rs 2761.55. The stock was the fourth biggest loser in 'A' the BSE, 1.07 lakh shares were traded on the counter so far as against the average daily volumes of 57942 shares in the past one month. Authum Investment & Infrastructure Ltd dropped 4.76% to Rs 2554.3. The stock was the fifth biggest loser in 'A' the BSE, 4927 shares were traded on the counter so far as against the average daily volumes of 12390 shares in the past one month.

India Ratings affirms ratings of Polyplex Corporation with 'stable' outlook
India Ratings affirms ratings of Polyplex Corporation with 'stable' outlook

Business Standard

time30 minutes ago

  • Business Standard

India Ratings affirms ratings of Polyplex Corporation with 'stable' outlook

Polyplex Corporation said that India Ratings and Research has affirmed the company's long-term rating at 'IND AA-' with 'stable' outlook. The agency has also affirmed the companys short-term rating at 'IND A1+. India Ratings and Research stated the affirmation reflects an improvement in the consolidated financial performance in FY25 while maintaining a strong credit profile, in line with the agencys expectations. The ratings continue to be supported by the companys strong position in the flexible packaging industry. The agency further said that developments that could, individually or collectively, lead to a positive rating action include an improvement in the scale and operating EBITDA, and maintaining the share of value-added products in the overall revenue and EBITDA mix, while maintaining the credit metrics on a sustained basis. However, delays, cost over-runs or a slower-than- expected ramp-up for new projects, a decline in the consolidated revenue or sustained deterioration in the operating EBITDA, large, debt-funded capex or acquisition, leading to sustained deterioration in the net leverage, and any adverse government regulatory action negatively impacting the sector could lead to an adverse rating action. Polyplex Corporation (PCL) has a product portfolio includes PET films (thin & thick), BOPP, cast polypropylene and blown polypropylene. These products are used in flexible packaging besides several industrial applications such as tapes, labels, thermal lamination, imaging and graphics, photo-voltaic and optical applications. The companys manufacturing facilities spread across India, the US, Thailand, Turkey and Indonesia. The scrip rose 0.21% to currently trade at Rs 1205.65 on the BSE.

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

Business Standard

time30 minutes ago

  • Business Standard

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

Lupin has announced the launch of Ipratropium Bromide Nasal Solution (nasal spray) in two strengths in the United States. Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store